Public comment:Lung cancer/Clinical practice guidelines for the treatment of lung cancer

From Cancer Guidelines Wiki
  • Statements regarding the inclusion/exclusion of issues should be clearly supported by scientific evidence, and specifically outline the relevance of the suggested material to the guidelines.
  • If you have identified any gaps or errors in the content please suggest suitable text for inclusion.
  • Attach any supporting references or newly published evidence to be considered by the author group for inclusion to your comment.

How to post a public comment

  1. Create a user account and/or log in with your details
  2. To post a comment, click the blue 'Make a new comment' link below
  3. Fill in the empty boxes
    Warning: You need to fill out the subject line and box!
  4. Attach supporting references and any new papers to go with your comment and to be considered by the author group for inclusion by clicking on "Attach academic evidence".
  5. Press 'save page' to post your comment!

In order to leave a comment, you must be logged into a Cancer Council Australia account.
Log in to your account Create your account


Thread titleRepliesLast modified
Clinical trials?014:59, 11 December 2017
lung cancer treatment pathway comments118:54, 21 December 2012
General comments for Clinical Practice Guidelines for the Treatment of Lung Cancer011:10, 20 September 2012
Lung cancer guideline feedback117:05, 6 July 2012
General Comment - MDT Meetings111:10, 5 June 2012
General Comment - Preamble119:33, 30 May 2012

Clinical trials?

On the Summary of Recommendations page I could see no reference to clinical trials as being an important potential path of treatment. Shouldn't clinical trials receive adequate focus in these Guidelines? Are clinical trials covered in the more detailed view of these Guidelines perhaps?

For many patients, trials are the best option for treatment. Especially as most lung cancer patients are diagnosed at an advanced Stage 3 or 4, and PBS-approved treatment options are often very limited.

Often trials have some trouble accruing enough patients, so including clinical trials in the treatment Guidelines might help with patient accrual.

(My thoughts from the patient perspective.)

Marilyn Nelson (talk)14:59, 11 December 2017

lung cancer treatment pathway comments

For inoperable Stage 3 lung cancer, combined modality chemoradiotherapy is clearly an optimal choice. My issue is getting radiotherapists to agree to treat large lung volumes for fear of radiaton pneumonitis. If this is a legitimate concern and if combined modality is the optimum way forward for these patients, then perhaps the radiation therapists need to clarify exactly what they are willing to radiate and conisder specialized (potentially more expensive) approaches such as IMRT or possibly sequential chemo followed by chemoradiotherapy.Thes issues are not clarified by the guidelines., 20 December 2012

Thank you for this query. The volume constraints that are recommended to limit risk of pneumonitis are listed in 2.4.1. We were unable to find any high level data indicating safety of IMRT over 3D conformal based on tumour size. In a population of patients (who were not selected on the basis of tumour size) sequential chemotherapy and chemoradiotherapy was associated with increased toxicity but without any survival advantage in a randomised trial published by Vokes et al (J Clin Oncol 2007; 25: 698), but I see that we have not addressed or referenced this particular topic.

Professor David Ball MB BS, MD, FRANCZR18:54, 21 December 2012

General comments for Clinical Practice Guidelines for the Treatment of Lung Cancer

I was pleased to see the Clinical Practice Guidelines for the Treatment of Lung Cancer released for public consultation. The Cancer Institute NSW is aware of the significant amount of work that has gone into revising these Guidelines, and I commend both Cancer Australia and the Cancer Council Australia for the thorough and inclusive process that has underpinned this review.

As a result of the inclusive and collaborative processes you have employed to review the Guidelines, they are very comprehensive and demonstrate the high standard of care we are able to provide in Australia. I have reviewed the Guidelines and do not have any comments to add to them, hence I, and the Cancer Institute NSW will not be submitting a response to the public consultation. The Cancer Institute NSW has also circulated the draft to relevant stakeholders and encouraged them to provide feedback directly to the wiki link.

The revised Guidelines reflect progress in the treatment of lung cancer since their original release in 2004. For more people, lung cancer is a treatable disease and the revised Guidelines demonstrate the options available to improve the survival of people with lung cancer. The Cancer Institute NSW is supportive of these Guidelines and look forward to working with Cancer Australia and the Cancer Council Australia to encourage their adoption throughout NSW.

Professor David Currow

Chief Cancer Officer, New South Wales

Chief Executive Officer, Cancer Institute, New South Wales

(Submitted in writing on 31 May 2012)

Professor David Currow11:10, 20 September 2012

Lung cancer guideline feedback

First up, this is an outstanding piece of work which the authors and organizing team should be very proud of. The sections are well set out and easily navigated. The quality of the opinions are excellent and well referenced. I was particularly pleased that the links are included back to PubMed and many of the articles can be retrieved direct on the fly. Discussions of evidence are robust and well informed. The ability to submit evidence is welcome (but may represent a rod for your own backs!).

Where this style excels is for reference before (or possibly even during) an MDM discussion where a particular facet of management is being contemplated. I took it for a test drive whilst filling in my MDM pro forma today and found several (minor) areas where our current practice was not well supported by the evidence. Given that this is a key role for the software it follows that fast navigation will be absolutely critical. Hence I will comment on this first.

The search box doesn't like typos (unsurprising) but if I search for cerebral metastases I get nothing, whilst brain metastases gets many hits but brain mets gets none. Some way of tagging the sections might help the searcher?

If I access via the Lung Cancer page and search for PET/CT I get a number of results for endometrial cancer. Can this be altered so whilst in the lung cancer guidelines search results only pertain to lung cancer? After all, in a lung cancer MDM if I need to look something up I don't want to wade through non-lung results. Conversely if I want to look up a non-lung topic I would specify the organ in that search. Maybe a "Search in Lung" as opposed to "Search all site", but better to have one box with smarter filters.

Another possibility would be some kind of grid for NSCLC where tags could be selected e.g. "stage IIa" "inoperable" and "radiotherapy" could be selected and the relevant article appears. It would have to be neat & tidy though, else would be a distraction from the main body of work. Alternatively, Advice for NSCLC and SCLC could be presented on a different coloured background to allow easy differentiation.

SCLC is still referred to as limited or extensive against 7th TNM staging, which will change with time as the evidence is reappraised I guess. With regards to scope, I assume the SCLC / NSCLC dichotomy has been chosen for pragmatic reasons, as I could find no mention of invasive adenocarcinoma of lepidic type (bronchoalveolar cell carcinoma), or the management of paraneoplastic manifestations, for instance. Not that evidence in these circumstances is thick on the ground.

There are a handful of minor typos and grammatical errors. Should these be commented on in individual sections and if so will the comments remain there to reveal my pedantry forever, or are comments relayed to the author for amendment as needed and then deleted or shunted off into storage? Minor typos etc tend to get kept on wikis but are mainly irrelevant.

Are sections that are recently updated marked out as such? This would be one way of keeping up to date with new evidence. EDIT: I see that can be done after registration, thanks.

Very minor one - when browsing in Safari 5.1.7 on OSX 10.7.3 pressing enter after typing a search query doesn't work, search has to be manually clicked. Works fine on Chrome 20, Firefox 12.0 & Opera 12 though (multiple hits of enter needed). I like the boolean search. I haven't looked at the site in IE, but the formatting is excellent on OSX browsers.

Clearly the guidance relates to treatment only at present - are there plans to extend to investigation etc?

Overall, I think this a fine body of work that should form a standard to which others aspire. Congratulations to all involved. I gather this is a world first, and you are certainly leading the way. Thanks for all your hard work.

Dr Ben Brockway16:50, 6 July 2012

I have discussed the guidelines with Ben and essentially endorse all of his comments, with little extra to add.

I agree that the beauty of this format is that it will be very practical for use at MDTs, and has the potential to clearly inform decision making at that meeting in real time. From that point of view it would be great if the few typos and "gremlins" in the search engine etc could be ironed out, in order to make them as easy as possible to utilise. However given the world first status of using of the Wiki format/platform for such guideline, these issues are remarkably few.


General Comment - MDT Meetings

Multidisciplinary lung cancer meetings for patients with lung cancer

The management of patients with cancer is complex. Formal multidisciplinary team (MDT) meetings have been widely promoted to improve coordination, communication and decision making in cancer management.1 The use of MDT may be particularly important for patients with thoracic malignancies.2,3 Research demonstrating the effectiveness of MDT in improving cancer outcomes is relatively scarce.1,4

One study from Scotland, compared the treatment and survival of patients with inoperable non-small cell lung cancer (NSCLC) at a single institution treated before and after the introduction of a MDT. It found an increase in the use of chemotherapy from 7% to 23% and an association with an increase in median survival from 3.2 to 6.6 months.5 However, as the two periods studied (1997 and 2001) were separated by 4 years, the observed differences might have been due to factors other than MDT meetings alone.

An Australian study subsequently looked at patients with inoperable NSCLC diagnosed and managed at a single institution over a one-year period. Those patients whose case had been discussed at a multidisciplinary meeting had better survival than those whose case was not discussed (mean survival; 280 days vs. 205 days, p = 0.048).6 Another Australian study, looking at al patients with a new lung cancer diagnosis (all stages of both SCLC and NSCLC, not necessarily pathologically proven). They found patients presented at MDT meetings were more likely to receive radiotherapy (66% vs. 33%, p < .001); chemotherapy (46% vs. 29%; p < .001); and referral to palliative care (66% vs. 53%; p < .001).7 In that study MDT meeting discussion did not influence survival.

Experts attending a national Australian lung cancer meeting were surveyed regarding multidisciplinary lung cancer meetings.8 The vast majority of respondents recommended the attendance of each of Respiratory physicians, Cardiothoracic surgeons, Radiation oncologists, Medical oncologists, Nuclear medicine physicians, Radiologists, Pathologists, Palliative care physicians and Nurse coordinators. In most cases meetings met clinicians’ needs. However there were concerns about adequate attendance and resources (including e.g. adequate time, computerised databases).

Evidence Summary

-Patients with lung cancer benefit from multidisciplinary team discussion -Multidisciplinary lung cancer meetings need to be adequately attended and resourced


- Patients with lung cancer should routinely be discussed at multidisciplinary lung cancer meetings - Multidisciplinary lung cancer meetings should be adequately attended and resourced


1. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol 2006; 7: 935–43. 2. Alberts WM, Bepler G, Hazelton T, Ruckdeschel JC, Williams JH. Lung cancer. Practice organization. Chest 2003; 123 (1 Suppl): 332S–337S. 3. Coory M, Gkolia P, Yang IA, Bowman RV, Fong KM. Systematic review of multidisciplinary teams in the management of lung cancer. Lung Cancer 2008; 60: 14–21. 4. Wright F, De Vito C, Langer B, Hunter A. Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer 2007; 43: 1002–10. 5. Forrest LM, McMillan DC, McArdle CS, Dunlop DJ. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005; 93: 977–8. 6. Bydder S, Nowak A, Marion K, Phillips M, Atun R. The impact of case discussion at a multidisciplinary team meeting on the treatment and survival of patients with inoperable non-small cell lung cancer. Intern Med J. 2009; 39: 838-41. 7. Boxer MM, Vinod SK, Shafiq J, Duggan KJ. Do multidisciplinary team meetings make a difference in the management of lung cancer? Cancer. 2011; 117:5112-20. 8. Bydder S, Hasani A, Broderick C, Semmens J. Lung cancer multidisciplinary team meetings: A survey of participants at a national conference. J Med Imaging Radiat Oncol. 2010; 54: 146-51.

Tahlia Moss15:25, 30 May 2012

Thank you for bringing this to our attention. I agree that we should have a section on multidisciplinary care and meetings, but it is not within the scope of the present document, and it was not one of the topics we addressed. I think it might be best placed in a section on initial assessment/patient selection for treatment, which is yet to be written and is planned for the future. This will require a systematic review including a search strategy and literature appraisal.


General Comment - Preamble

We propose the final document should include a Preamble to incorporate new developments in the staging process, the new sub-classification of lung cancer by histopathology and molecular pathology, and the implications for treatment and tissue acquisition. The Preamble could also address the criteria for ‘operability’ where reference is made. This might be on the basis of other medical considerations.

Tahlia Moss15:25, 30 May 2012

Many thanks for this suggestion. It had been my intention to write a foreword to the guidelines once we have reviewed all the comments. These are all excellent points for inclusion.